Preoperative chemoradiation with cisplatin-irrinotecan compared with carboplatin-paclitaxel in esophageal cancer.
Phase 3
- Conditions
- C15.1-C15.Esophageal Cancer.-Thoracic part of oesophagus-Abdominal part of oesophagus-Cardia
- Registration Number
- IRCT20141102019783N5
- Lead Sponsor
- Vice chancellor for research, Mashhad University of Medical Sciencesice
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Primary esophageal cancer(adenocarcinoma or squamous cell carcinoma) No distant metastasis Maximum age 75 years Performance Status>70% Stable hematologic status Normal liver and kidney function Patient consent suitable for surgery
Exclusion Criteria
Metastatic disease Cervical Esophageal Cancer Thracheoesophageal fistula Previous or current another malignant disease Any major surgery within the past 4 weeks.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Survival Rate. Timepoint: 1- Every 3 months after start of intervention. 2- Following every cycle of chemotherapy. Method of measurement: Months that patient is without any sign or recurrent disease and survive after start of intervention.
- Secondary Outcome Measures
Name Time Method 1- Disease Free Survival (DFS) 2- Treatment toxicity. Timepoint: Every 3 months after start of intervention also following every cycle of chemotherapy. Method of measurement: Months that patient survive after start of intervention.